Ensysce Biosciences, Inc. Common Stock (ENSC) Stock Price

ENSCStock

$0.40−82.39%52W

Market Cap$7.84M

P/E—

PEG Ratio—

Div yield—

Beta0.99

ENSC Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-18.54%

Price vs S&P 500 (4W)40.77%

VGM Score47.76

Book Value / Share (Quarterly)$0.70

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)26.21%

Cash Flow / Share (Quarterly)$-1.05

Price vs S&P 500 (YTD)-72.72%

Net Profit Margin (TTM)-250.36%

EPS (TTM)$-3.34

10-Day Avg Trading Volume3.67M

EPS Excl Extra (TTM)$-3.34

EPS (Annual)$-3.98

ROI (Annual)-199.18%

Net Profit Margin (5Y Avg)-522.58%

Cash / Share (Quarterly)$0.08

Revenue Growth QoQ (YoY)-27.18%

ROA (Last FY)-142.62%

Revenue Growth TTM (YoY)-24.36%

EBITD / Share (TTM)$-3.02

ROE (5Y Avg)-10.24%

Operating Margin (TTM)-251.40%

Cash Flow / Share (Annual)$-5.52

P/B Ratio1.63x

P/B Ratio (Quarterly)1.04x

Net Income / Employee (Annual)$-1,272,000

EV / Revenue (TTM)1.00x

Net Interest Coverage (TTM)-541.15x

ROA (TTM)-256.59%

EV / EBITDA (TTM)6.43x

EPS Incl Extra (Annual)$-3.98

Current Ratio (Annual)2.42x

Quick Ratio (Quarterly)0.27x

3-Month Avg Trading Volume11.44M

52-Week Price Return-82.39%

Revenue / Employee (TTM)$588,500

Tangible BV / Share (Quarterly)$0.52

P/S Ratio (Annual)1.03x

Asset Turnover (Annual)0.93x

52-Week High$2.75

Operating Margin (5Y Avg)-498.67%

EPS Excl Extra (Annual)$-3.98

26-Week Price Return-7.29%

Quick Ratio (Annual)1.65x

13-Week Price Return11.73%

Total Debt / Equity (Annual)0.08x

Current Ratio (Quarterly)0.71x

Enterprise Value$4.73M

Asset Turnover (TTM)1.02x

Revenue / Employee (Annual)$633,300

Pretax Margin (Annual)-200.85%

Cash / Share (Annual)$2.57

3-Month Return Std Dev143.69%

Net Income / Employee (TTM)$-1,473,300

ROE (Last FY)-215.28%

Net Interest Coverage (Annual)-624.97x

EPS Basic Excl Extra (Annual)$-3.98

Receivables Turnover (TTM)427.99x

Total Debt / Equity (Quarterly)0.10x

EPS Incl Extra (TTM)$-3.34

Receivables Turnover (Annual)7.02x

ROI (TTM)-332.77%

P/S Ratio (TTM)1.11x

Pretax Margin (5Y Avg)-523.41%

Revenue / Share (Annual)$1.98

Tangible BV / Share (Annual)$-6.95

Price vs S&P 500 (52W)-100.70%

Year-to-Date Return-60.76%

5-Day Price Return-6.23%

EPS Normalized (Annual)$-3.98

ROA (5Y Avg)-217.56%

Net Profit Margin (Annual)-200.84%

Month-to-Date Return42.69%

Cash Flow / Share (TTM)$-7.50

EBITD / Share (Annual)$-4.00

Operating Margin (Annual)-202.12%

LT Debt / Equity (Annual)0.00x

ROI (5Y Avg)-9.12%

LT Debt / Equity (Quarterly)0.00x

EPS Basic Excl Extra (TTM)$-3.34

P/TBV (Quarterly)1.86x

P/B Ratio (Annual)2.18x

Pretax Margin (TTM)-250.37%

Book Value / Share (Annual)$2.73

Price vs S&P 500 (13W)8.94%

Beta0.99x

Revenue / Share (TTM)$0.69

ROE (TTM)-374.96%

52-Week Low$0.23

vGradeB

gGradeD

mGradeC

vgmGradeC

ENSC Earnings Surprise History

Q2 25-0.79est. -1.28

Q3 25-1.29est. -0.93

Q4 25-0.75est. -1.26

Q1 26-0.52est. -0.73

Q2 26-0.20est. -0.50

ENSC Analyst Recommendations

Apr 2024

May 2024

Jun 2024

Jul 2024

4.14

Industry Peers — Pharmaceuticals(571)

Symbol	Value Score	Growth Score	Momentum Score	Price
ENSCEnsysce Biosciences, Inc. Common Stock	B	D	C	$0.40
LLYEli Lilly & Co.	D	B	B	$1233.66
JNJJohnson & Johnson	D	C	B	$273.14
ABBVABBVIE INC.	D	C	B	$265.79
MRKMerck & Co., Inc.	D	C	A	$156.45
NVSNovartis AG	C	C	C	$159.98
AZNAstraZeneca PLC	C	B	C	$169.66
NVONovo-Nordisk A/S	B	C	C	$48.66
ABTAbbott Laboratories	C	C	B	$116.13
PFEPfizer Inc.	C	D	C	$28.57
VRTXVertex Pharmaceuticals Inc	D	C	B	$552.85
BMYBristol-Myers Squibb Co.	B	B	B	$67.92
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	C	C	$46.02
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	B	C	C	$52.07
REGNRegeneron Pharmaceuticals Inc	C	C	B	$833.56
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	C	$18.35
TEVATeva Pharmaceutical Industries Limited American Depositary Shares	C	C	C	$38.10
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	C	$376.37
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	B	$62.07
ALNYAlnylam Pharmaceuticals, Inc.	D	A	D	$240.08
ZTSZOETIS INC.	B	C	D	$77.29
INSMInsmed, Inc.	F	A	C	$123.89
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	$36.47
UTHRUnited Therapeutics Corp	C	C	C	$518.53
GMABGenmab A/S ADS	C	C	B	$34.36
VTRSViatris Inc. Common Stock	B	C	B	$16.72
JAZZJazz Pharmaceuticals, Inc.	B	C	B	$260.23
ASNDAscendis Pharma A/S Ordinary Share	D	A	C	$252.99
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	$80.40
CORTCorcept Therapeutics Inc.	F	C	A	$123.57
BMRNBioMarin Pharmaceuticals Inc	C	C	C	$66.12
ARWRArrowhead Research Corporation	D	A	B	$88.88
ELANElanco Animal Health Incorporated Common Stock	C	B	B	$25.09
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	C	$512.16
CYTKCytokinetics Inc.	F	D	B	$77.46
AXSMAxsome Therapeutics, Inc	D	B	C	$205.48
SMMTSummit Therapeutics Inc. Common Stock	F	—	D	$13.36
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	$63.57
ABVXAbivax SA American Depositary Shares	—	—	C	$117.93
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	D	C	$12.34
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	$368.02
NUVLNuvalent, Inc. Class A Common Stock	—	—	B	$123.96
PTGXProtagonist Therapeutics, Inc	F	B	A	$150.59
SYRESpyre Therapeutics, Inc. Common Stock	—	—	A	$107.36
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	$84.86
TGTXTG Therapeutics, Inc.	D	B	A	$55.42
ALKSAlkermes Inc. plc	D	C	B	$49.21
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	$113.35
ORKAOruka Therapeutics, Inc. Common Stock	F	—	A	$101.82
BLTEBelite Bio, Inc American Depositary Shares	—	—	B	$161.68
COGTCogent Biosciences, Inc. Common Stock	F	—	B	$36.80

About Ensysce Biosciences, Inc. Common Stock

Ensysce Biosciences is a clinical-stage biotech company developing safer opioid medications using proprietary abuse-resistant and overdose-protection technologies. The company's pipeline includes two drug platforms—the TAAP platform for abuse resistance and the MPAR platform for overdose protection—targeting the severe pain management market while reducing addiction and overdose risk. By addressing a critical unmet need, Ensysce aims to provide healthcare providers with effective pain treatment options that limit potential for drug abuse.